AMAida Mohamadi

Aida Mohamadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aida Mohamadi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Computed tomography of interstitial lung disease in systemic sclerosis: dataset and deep learning model for pulmonary lesion segmentation

    by Amir M. Vahdani, Aida Mohamadi, Sepehr Nayebirad, Shayan Forghani, Elaheh Karimi, Yousef Vojgani, Zahra Tamartash, Mehrnaz Asadi, Leila Aghaghazvini, Farhad Gharibdoost, et al.

    Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a major cause of morbidity and mortality in systemic sclerosis patients. High-resolution computed tomography (HRCT) plays a crucial role in SSc-ILD diagnosis and management. In this study, we aimed to develop and evaluate a deep learning-based automated segmentation model for quantifying SSc-ILD lesions in HRCT images and assess its clinical relevance. Methods. We developed a convolutional neural network model to segment normal lung, established fibrosis (EF), and ground-glass opacity (GGO) in HRCT scans from 40 SSc-ILD patients. The model was trained and evaluated using 8-fold cross-validation. Segmentation performance was assessed using the Dice similarity coefficient (DSC). Correlations between predicted lesion volumes and pulmonary function test (PFT) metrics were analyzed using Spearman’s ρ. Results. Our model achieved a total lesion (EF+GGO) DSC of 78%. Class-wise segmentation performance was lower for EF (DSC: 70%) compared to GGO (DSC: 73%). Predicted lesion volumes showed significant negative correlations with forced expiratory volume in one second (FEV1) (ρ=-0.64, p<0.001) and FEV1/forced vital capacity (ρ=-0.73, p<0.001). We also created the SICCS dataset, a public dataset of SSc-ILD HRCT images with expert-annotated segmentation labels. Conclusions. Deep learning-based automated segmentation can help quantify SSc-ILD lesions in HRCT images and provide clinically relevant information. The model’s performance is comparable to previous studies, and the predicted lesion volumes correlate significantly with PFT metrics. This approach shows promise for aiding in SSc-ILD diagnosis, monitoring, and clinical decision-making, although further validation with larger datasets is needed.


  • Open Access

    New‐onset ANCA‐associated vasculitis presenting with neuropathy after COVID‐19 infection: A case report and literature review

    by Aida Mohamadi, Somayeh Soroureddin, Sepehr Nayebirad, Zahra Tamartash, Maryam Mohebbi, Hoda Kavosi

    Key Clinical Message: Coronavirus Disease 2019 (COVID‐19) is a viral infection caused by SARS‐CoV‐2, which can trigger autoimmune diseases such as antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis (AAV) that affect small and medium‐sized blood vessels in multiple organs. This study discusses a case with neuropathy and positive ANCA after COVID‐19 infection and reviews the literature on AAV following COVID‐19 infection. A 59‐year‐old man is presented that was referred to Shariati Hospital for evaluation of neurologic problems after a COVID‐19 infection. Initially, he had flu‐like symptoms. A few days later, he developed right distal upper and lower limb paresthesia. His electromyography (EMG) and nerve conduction velocity (NCV) results were consistent with polyneuropathy. Lumbar puncture (LP) was normal except for positive COVID‐19 polymerase chain reaction (PCR). The patient's paresthesia worsened. Laboratory data showed leukocytosis, anemia, thrombocytosis, high erythrocyte sedimentation rate (ESR), and C‐reactive protein (CRP). Perinuclear anti‐neutrophil cytoplasmic antibody (MPO‐ANCA) was positive. According to the results, vasculitis was the main differential diagnosis. The sural nerve biopsy was performed, and the result was consistent with small to medium‐sized vessel vasculitis. The patient was diagnosed with COVID‐induced AAV. He was prescribed methylprednisolone and cyclophosphamide and was discharged with prednisolone and cotrimoxazole. In this study, a unique case of AAV induced by COVID‐19 infection confirmed by nerve biopsy is presented. A review of the literature found 48 cases of new‐onset AAV in adults and pediatrics after COVID‐19 infection. Further research is needed to completely understand the relationship between COVID‐19.


  • Top Cited Papers
    Open Access

    Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis

    by Sepehr Nayebirad, Aida Mohamadi, Hannaneh Yousefi-Koma, Minoo Javadi, Kimia Farahmand, Reza Atef-Yekta, Zahra Tamartash, Mana Jameie, Amir Mohammad Mohammadzadegan, Hoda Kavosi

    Objectives: Interstitial lung disease (ILD) is an important manifestation of autoimmune diseases that can lead to morbidity and mortality. Although several autoantibodies have been linked with ILD presentation and adverse outcomes, the association of anti-Ro52 antibody with ILD is less studied. Hence, we investigated this association in various autoimmune diseases in the current study. Design: We designed a systematic review and meta-analysis and did a comprehensive search from inception until 2 January 2023. Data sources: A systematic search was conducted in four electronic databases: PubMed, Web of Science, Scopus and Embase. Eligibility criteria: Observational studies that reported ILD diagnosis (outcome) and anti-Ro antibody (exposure) status in any autoimmune conditions (population) were included. The association between rapidly progressive ILD (RP-ILD) and anti-Ro52 was studied in idiopathic inflammatory myopathies (IIM). Data extraction and synthesis: Collected data included study characteristics and ORs with 95% CIs. Quality assessment was performed using a modified version of the Newcastle-Ottawa Scale for cross-sectional studies. Random effects meta-analysis was used to pool the effect estimates. Results: A total of 2353 studies were identified, from which 59 articles met the eligibility criteria. Anti-Ro52/SSA positivity was associated with ILD in all autoimmune disease subgroups: IIM (OR=3.08; 95% CI: 2.18 to 4.35; p value2=49%), systemic lupus (OR=2.43; 95% CI: 1.02 to 5.79; p=0.046; I2=71%), Sjogren (OR=1.77; 95% CI: 1.09 to 2.87; p=0.021; I2=73%), systemic sclerosis (OR=1.71; 95% CI: 1.04 to 2.83; p=0.036; I2=43%), mixed connective tissue disease (OR=3.34; 95% CI: 1.82 to 6.13; p2=0%). Additionally, anti-Ro52-positive myopathy patients were more likely to have simultaneous RP-ILD (OR=2.69; 95% CI:1.50 to 4.83; p2=71%). Conclusion: Anti-Ro52/SSA positivity is associated with a higher frequency of ILD diagnosis in various autoimmune diseases. Anti-Ro52/SSA is also linked with a more severe lung involvement (RP-ILD). Future studies can investigate the benefits of screening for anti-Ro52 and its association with ILD development. PROSPERO registration number: CRD42022381447.